SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...

Traditionally, a transrectal biopsy was the standard procedure to test for prostate cancer if a prostate-specific antigen blood test was elevated and/or a digital rectal exam was flagged. During a ...

Scientists use a metric called “area under the curve” or AUC to assess how well the test performed. An AUC of 1 is a perfect ...

Discover a study showing how repeating elevated PSA tests can prevent unnecessary procedures, while persistent elevations ...

A Yale-led study examines the potential environmental benefits of more carefully selecting patients for prostate biopsy in a way that can also spare low-yield and potentially harmful procedures. Yale ...

The American Cancer Society estimates that 288,300 new cases of prostate cancer will be diagnosed in 2023. While the overall 5-year survival rate is 97%, that number goes down significantly if the ...

Please provide your email address to receive an email when new articles are posted on . Combining an MRI-targeted biopsy approach with the Stockholm3 blood test for prostate cancer screening reduced ...

Stockholm3 blood test could have reduced unnecessary biopsies by almost half compared with PSA screening alone. Stockholm3 demonstrated superior specificity across all ethnic groups. Perspective from ...

A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...

AIIMS radiologist stresses importance of early prostate cancer screening, starting at age 50, or earlier for those with risk factors, for effective management.